Press release content from Business Wire. The AP news staff was not involved in its creation.
ForSight Robotics Raises $10 Million from Eclipse Ventures and Mithril Capital in Seed Round
March 11, 2021 GMT
ForSight Robotics is developing a next-generation miniature robotic system to help democratize ophthalmic surgery worldwide. Pictured above is a component of the robot prototype. (Photo: Business Wire)
ForSight Robotics is developing a next-generation miniature robotic system to help democratize ophthalmic surgery worldwide. Pictured above is a component of the robot prototype. (Photo: Business Wire)
YOKENEAM, Israel (BUSINESS WIRE) Mar 11, 2021
ForSight Robotics today announced the company is developing a surgical robotic platform that will transform the future of ophthalmic surgery with a $10 million seed round led by Eclipse Ventures and joined by Mithril Capital.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Masimo Monitoring Solutions Promote Newborn and Maternal Safety
March 8, 2021 GMT
Masimo Newborn Sensor (Photo: Masimo)
NEUCHATEL, Switzerland (BUSINESS WIRE) Mar 8, 2021
Masimo (NASDAQ: MASI) provides a variety of innovative monitoring solutions designed to improve maternal and newborn safety during childbirth and the critical first minutes of life. Masimo SET ® pulse oximetry’s ability to measure during motion and low perfusion has helped newborns, neonates, and pediatric patients like no other pulse oximetry. Not only has Masimo SET ® helped clinicians reduce retinopathy of prematurity (ROP) 1 and improve screening for critical congenital heart disease (CCHD), 2-10 but it has helped push the standard of care for babies to new heights the evidence from CCHD studies with SET ®, for example, has been used in the establishment of screening guidelines used around the world. 11
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Foundation Fighting Blindness To Jointly Host Online Continuing Medical Education (CME, COPE) Webinar
March 2, 2021 GMT
(PRNewsfoto/Foundation Fighting Blindness)
COLUMBIA, Md., March 2, 2021 /PRNewswire/ The Foundation Fighting Blindness, the world’s leading private funding source for retinal degenerative disease research, will host an online continuing medical education (CME and COPE) course on Monday, April 5, 2021, at 7:00 p.m. Eastern Time.
More than 40 clinical trials for emerging retinal degenerative disease therapies are underway. The studies provide hope for patients and the opportunity for them to participate in the research.
Press release content from Business Wire. The AP news staff was not involved in its creation.
GenSight Biologics Announces Publication of Results from LUMEVOQ® Phase I/IIa Clinical Trial REVEAL in BioDrugs
February 15, 2021 GMT
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the journal
BioDrugs has published results from REVEAL, the Phase I/IIa clinical trial that evaluated the safety of LUMEVOQ ® gene therapy in subjects with
ND4 Leber Hereditary Optic Neuropathy (LHON) and determined the dose subsequently used in the Phase III trials RESCUE and REVERSE.